Feasibility of intravitreal erythropoietin injections in humans.

作者:	W A Lagrèze, N Feltgen, M Bach, T Jehle
语言:	Eng.
日期:	2009-11-26
学报:	The British journal of ophthalmology (1468-2079)
发行:	Br J Ophthalmol. 2009 Dec;93(12):1667-71
摘要:	BACKGROUND/ AIMS: Preclinical data suggest that intravitreally administered erythropoietin (EPO) is both neuroprotective and safe. In a small pilot series, we intended to assess the feasibility of intravitreal EPO injections in humans. METHODS: Three patients with acute vascular occlusion of the posterior pole received a single intravitreal EPO injection of 2000 U. Immediately before the injection and over the ensuing 3 months, these patients were closely monitored by measuring visual acuity, visual fields, intraocular pressure, the electroretinogram, the haematocrit and serum EPO levels. RESULTS: Over the observational period, most parameters remained unchanged except for a short-term rise of serum EPO levels, which, however, did not exceeded normal serum levels. No injection-related toxicity was observed. CONCLUSION: Based on this limited set of data, a single EPO injection of 2000 U, a dose adapted from previous in vivo studies, is feasible and seems to induce no obvious damage. Hence, further investigations of this therapeutic approach appear justified.
版权:	The British journal of ophthalmology Universitäts-Augenklinik, Killianstr. 5, 79106 Freiburg, Germany. mail lagreze.de
全文:	DOI - The British journal of ophthalmology (DOI) EBSCO - HTML (需要捐款) HighWire Press - HTML (需要捐款) Ovid Technologies, Inc. - HTML (需要捐款)
科目:	Aged, Electroretinography, Epoetin Alfa, Erythropoietin, Feasibility Studies, Female, Humans, Injections, Intraocular, Intraocular Pressure, Male, Neuroprotective Agents, Optic Neuropathy, Ischemic, Pilot Projects, Retinal Artery Occlusion, Visual Acuity, Visual Fields, Vitreous Body